Drug Profile

LTZ 232

Alternative Names: LTZ-232

Latest Information Update: 10 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator LTZ Therapeutics
Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity; Macrophage activation; Natural killer cell stimulants; Phagocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

08 Jul 2026 Preclinical trials in Solid tumours in USA (Parenteral), prior to July 2026
08 Jul 2026 LTZ Therapeutics received IND clearnece from the US FDA for the initiation of phase I trial for Colorectal cancer and other Solid tumours
07 Jul 2026 LTZ Therapeutics plans a phase I trial for Colorectal cancer (Metastatic cancer, Late-stage disease) and other Solid tumours in the US (Parenteral) in fourth quarter of 2026

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com